Ra Pharmaceuticals, Inc.
(NASDAQ : RARX)

( )
RARX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
ABBVAbbVie, Inc. -0.07%90.801.9%$1163.97m
BMYBristol-Myers Squibb Co. -0.40%59.961.0%$1001.87m
JNJJohnson & Johnson -0.03%148.650.7%$982.92m
PFEPfizer Inc. -0.19%36.080.9%$949.54m
MRKMerck & Co., Inc. -0.02%82.040.7%$858.10m
LLYEli Lilly & Co. 0.00%152.531.1%$521.62m
AZNAstraZeneca Plc 0.31%55.181.2%$292.33m
NVSNovartis AG 0.62%86.230.2%$149.77m
GSKGlaxoSmithKline Plc -0.26%42.000.2%$131.76m
NVONovo Nordisk A/S 1.13%65.420.1%$89.71m
SNYSanofi 0.30%49.730.2%$77.19m
RGENRepligen Corp. -4.66%127.157.1%$70.91m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.72%66.200.0%$51.62m
TPTXTurning Point Therapeutics, Inc. -0.28%70.190.0%$41.11m
RETAReata Pharmaceuticals, Inc. -3.50%135.423.4%$35.66m

Company Profile

Ra Pharma is developing Cyclomimetics, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules. Ra Pharma’s peptide-like molecules are highly-stable, synthetic products with chemical structures that offer intrinsic cell permeability. Ra Pharma is leveraging its ability to rapidly generate drug candidates to develop its own portfolio of products and partnerships focused on intracellular protein-protein interactions and other innovative approaches to addressing unmet medical needs.